Oraya scores $42M for eye radiation treatments
Oraya Therapeutics, maker of radiosurgical tools used to treat eye diseases, has brought in $42 million in a third round of funding from Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.
Based in Newark, Calif., the company says it will use its new financing to widen its overseas clinical trials. It hopes to earn international approval and clearance for commercialization. Called the IRay system, its lead treatment can deliver precise doses of radiation to parts of the eye to slow age-related degeneration.
Oraya has raised $22 million to date.
Next Story: Data analytics provider Truviso takes $3M bridge, preps for third round of capital
Previous Story: Apps or browser? GetJar vs. Google on the future of mobile services
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.